Welcome to UroGen®
UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies.
Innovation that
champions patients
Possibilities
brought to life
Our story
is dynamic
Explore UroGen news
May 7, 2024
UroGen Pharma to Participate at Upcoming Investor Conferences
about UroGen Pharma to Participate at Upcoming Investor Conferences
May 5, 2024
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
about New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 4, 2024
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
about UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 4, 2024
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
about New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 3, 2024
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
about UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
Apr 17, 2024
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
about UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Apr 15, 2024
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
about UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Apr 3, 2024
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
about UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Mar 14, 2024
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
about UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
Mar 8, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)